• E David, A Belot, J-C Lega, I Durieu, and C Rousset-Jablonski.
• Service de médecine interne et pathologie vasculaire, centre hospitalier Lyon Sud, hospices civils de Lyon, université Claude-Bernard Lyon 1, Lyon, France. Electronic address: emmanuelle.david01@chu-lyon.fr.
• Rev Med Interne. 2021 Jul 1; 42 (7): 498504498-504.

AbstractInfection with human papillomavirus (HPV) is one of the most widespread sexually transmitted diseases and the main risk factor for cervical cancer. Underlying conditions, like immunosuppression, favour the persistence and the progression of cervical lesions to an aggressive form. Patients with autoimmune diseases, and particularly systemic lupus erythematosus (SLE), may be prone to HPV infection and cervical dysplasia. However, the risk factors for developing persistent HPV-related infection, dysplasia and cancer are not identified for patients with SLE. The existence of an increased risk of cervical cancer compared to the general population remains debated. Thus, HPV vaccine is recommended for SLE patients as well as for the general population. Vaccine coverage of SLE patients is not known in France. Adolescents with chronic health condition seem to be insufficiently vaccinated regarding their vulnerability to infectious diseases. Strategies are required to decrease HPV vaccination barriers.Copyright © 2021 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

20 keywords...

hide…